Thermogenic composition and benzazepine thermogenics
CA 2282390 A1 · Owner: Takeda Chemical Industries, Ltd. · Inventors: Furuyama, Naoki; Fujisawa, Yukio; Ishihara, Yuji
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The object of the present invention is to provide a prophylactic and/or therapeutic drug for obesity and obesity-associated diseases or diabetes with a reduced risk for central side effects and high universality in usage. Another object of the present inventio is to provide a pharmaceutical composition comprising a compound of formula (I) wherein Ar represents phenyl , which may be substituted and/or condensed; n represents an integer of 1 to 10; R represents hydrogen or a hydrocarbon group which may be substituted which , may not be the same in its n occurrences; R may be bound to either Ar or a substituent for Ar; Y represents an amino group which may be substituted or a …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 16, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended April 16, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 16, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.